SLC6A4 Gene — Serotonin Transporter

Migration, Crosslink

📖

SLC6A4 Gene — Serotonin Transporter

active

wiki page Created: 2026-04-02T07:19:18 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-slc6a4

📖 Wiki Page

gene1892 wordssynced 2026-04-02

SLC6A4 Gene — Solute Carrier Family 6 Member 4

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A4 Gene — Serotonin Transporter</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC6A4 (SERT, 5HTT)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6532</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000108576</td>
</tr>
<tr>
<td class="label">Uniprot ID</td>
<td>P31645</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>630 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~70 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>SERT, 5HTT, SAT2, hSERT</td>
</tr>
<tr>
<td class="label">Step</td>
<td>Process</td>
</tr>
<tr>
<td class="label">1</td>
<td>Na+ binding to extracellular site</td>
</tr>
<tr>
<td class="label">2</td>
<td>Serotonin binding</td>
</tr>
<tr>
<td class="label">3</td>
<td>Cl- binding</td>
</tr>
<tr>
<td class="label">4</td>
<td>Conformational change</td>
</tr>
<tr>
<td class="label">5</td>
<td>Substrate release inside</td>
</tr>
<tr>
<td class="label">6</td>
<td>Return to outward-facing state</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Brand Names</td>
</tr>
<tr>
<td class="label">Fluoxetine</td>
<td>Prozac, Sarafem</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>Zolo

...

SLC6A4 Gene — Solute Carrier Family 6 Member 4

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC6A4 Gene — Serotonin Transporter</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC6A4 (SERT, 5HTT)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>17q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6532</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000108576</td>
</tr>
<tr>
<td class="label">Uniprot ID</td>
<td>P31645</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>630 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~70 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>SERT, 5HTT, SAT2, hSERT</td>
</tr>
<tr>
<td class="label">Step</td>
<td>Process</td>
</tr>
<tr>
<td class="label">1</td>
<td>Na+ binding to extracellular site</td>
</tr>
<tr>
<td class="label">2</td>
<td>Serotonin binding</td>
</tr>
<tr>
<td class="label">3</td>
<td>Cl- binding</td>
</tr>
<tr>
<td class="label">4</td>
<td>Conformational change</td>
</tr>
<tr>
<td class="label">5</td>
<td>Substrate release inside</td>
</tr>
<tr>
<td class="label">6</td>
<td>Return to outward-facing state</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Brand Names</td>
</tr>
<tr>
<td class="label">Fluoxetine</td>
<td>Prozac, Sarafem</td>
</tr>
<tr>
<td class="label">Sertraline</td>
<td>Zoloft</td>
</tr>
<tr>
<td class="label">Paroxetine</td>
<td>Paxil</td>
</tr>
<tr>
<td class="label">Citalopram</td>
<td>Celexa</td>
</tr>
<tr>
<td class="label">Escitalopram</td>
<td>Lexapro</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">SLC6A3 (DAT)</td>
<td>Family member</td>
</tr>
<tr>
<td class="label">SLC6A2 (NET)</td>
<td>Family member</td>
</tr>
<tr>
<td class="label">TPH2</td>
<td>Enzyme</td>
</tr>
<tr>
<td class="label">MAOA</td>
<td>Enzyme</td>
</tr>
<tr>
<td class="label">HTR1A-HTR7</td>
<td>Receptors</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">ANXIETY</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">176 edges</a></td>
</tr>
</table>

Pathway Diagram

Mermaid diagram (expand to render)

SLC6A4 Gene — Solute Carrier Family 6 Member 4

Introduction

SLC6A4 (Solute Carrier Family 6 Member 4), also known as the serotonin transporter (SERT) or 5-HTT, is a membrane protein that mediates the reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft back into presynaptic neurons. This reuptake is the primary mechanism for terminating serotonin signaling, making SLC6A4 a critical regulator of serotonergic neurotransmission. The serotonin transporter serves as the principal regulator of serotonergic signaling duration and intensity, fundamentally influencing mood, cognition, sleep, and numerous other neurological processes. Notably, SLC6A4 has been increasingly implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, where serotonergic dysfunction contributes to disease progression and symptomology [@murphy2008].

The serotonin transporter represents one of the most extensively studied proteins in neuropsychopharmacology due to its central role in the mechanism of action of selective serotonin reuptake inhibitors (SSRIs), the first-line pharmacological treatment for depression and anxiety disorders. Understanding SLC6A4 structure, function, and regulation provides critical insights into both normal brain function and the pathophysiology of multiple neurological conditions.

Gene Information

Genomic Structure

The SLC6A4 gene is located on chromosome 17q11.2 and consists of 14 exons spanning approximately 40 kb. The gene encodes a protein of 630 amino acids with a molecular weight of approximately 70 kDa. The promoter region contains several regulatory elements including the well-characterized 5-HTTLPR polymorphism and additional variable number tandem repeat (VNTR) regions within intron 2 [@canli2006].

Regulatory Polymorphisms

5-HTTLPR (Serotonin-Transporter-Linked Polymorphic Region)

The most extensively studied polymorphism in SLC6A4 is a 5-HTTLPR located in the promoter region:

Short (S) allele: 44 bp deletion, associated with reduced transcriptional efficiency (~30-40% lower expression)
Long (L) allele: 44 bp insertion, associated with higher baseline expression
L_A and L_G variants: The L allele has two sub-variants (L_A and L_G), where L_G shows similar activity to the S allele

This polymorphism has been extensively studied in relation to:

Depression susceptibility and treatment response
Anxiety disorders
Stress vulnerability and resilience
Neurodegenerative disease risk [@stocker2006]
Neuroimaging phenotypes

STin2 VNTR

A variable number tandem repeat in intron 2 (STin2) containing 9, 10, or 12 copies of a 17-bp repeat:

The 12-repeat allele associated with higher expression in some studies
Implicated in various psychiatric conditions
May interact with 5-HTTLPR

Protein Structure and Function

Structural Features

SLC6A4 is a member of the neurotransmitter sodium symporter (NSS) family (SLC6A), which includes transporters for dopamine (DAT/SLC6A3), norepinephrine (NET/SLC6A2), and GABA (GATs/SLC6A). The protein contains:

12 transmembrane domains: Alpha-helical segments that span the membrane, forming the translocation pathway

Intracellular N- and C-termini: Regulatory domains containing phosphorylation sites and protein interaction motifs

Extracellular loops: Contain glycosylation sites important for protein folding and trafficking

Binding sites: For serotonin, sodium ions, and chloride ions

Transport Mechanism

SLC6A4 operates as a secondary active transporter utilizing the sodium gradient:

Sodium coupling: Two Na+ ions co-transported with each serotonin molecule

Chloride dependence: One Cl- ion also required for transport

Electrogenic transport: Net positive charge moved into the cell (3 Na+ + 5-HT vs 1 Cl-)

Voltage dependence: Transport rate depends on membrane potential

Substrate Specificity

SLC6A4 transports:

Serotonin (5-hydroxytryptamine, 5-HT) — primary substrate, Km ~ 0.1-1 μM
Tryptamine — lower affinity
Some hallucinogenic compounds — partial substrates (e.g., MDMA)
Amphetamine derivatives — some act as substrates, others as inhibitors

Conformational Cycle

The transport mechanism involves alternating access:

Outward-facing state: Substrate binding site accessible to extracellular space

Occluded state: Substrate and ions bound, channel closed

Inward-facing state: Substrate release to intracellular space

Return step: Transporter returns to outward-facing state

This cycle is driven by the electrochemical gradient for Na+ and can be inhibited by multiple compounds.

Regulation of SLC6A4

Transcriptional Regulation

Promoter activity: 5-HTTLPR genotype significantly affects promoter activity

Epigenetic modification: DNA methylation of promoter region correlates with gene expression

Activity-dependent regulation: Neuronal activity can modulate SLC6A4 expression

Hormonal regulation: Cortisol and other hormones affect transporter expression

Post-Translational Regulation

Phosphorylation: PKC-mediated phosphorylation reduces transport activity

Glycosylation: N-linked glycosylation required for proper membrane targeting

Palmitoylation: Affects membrane localization and function

Protein interactions: Interacts with scaffolding proteins (e.g., PSD-95, SNX27)

Membrane Trafficking

SLC6A4 is dynamically regulated by endocytosis and recycling
Psychostimulants can cause internalization
Agonist binding triggers regulatory internalization

Role in Neurodegenerative Diseases

Alzheimer's Disease

SLC6A4 has been implicated in Alzheimer's disease through several mechanisms [@stocker2006]:

Serotonergic dysfunction: AD is associated with reduced serotonergic signaling due to:

Loss of serotonergic neurons in the raphe nuclei
Reduced tryptophan availability
Altered receptor and transporter expression

Amyloid interaction: Aβ peptides may affect SERT expression and function:

Aβ can alter serotonin transporter phosphorylation
May affect transporter trafficking to membrane

Neuroinflammation: Inflammatory processes modulate serotonin transporter:

Cytokines can reduce SLC6A4 expression
Neuroinflammation linked to depression in AD

Treatment target: SSRIs have been investigated for cognitive benefits in AD:

May reduce amyloid burden
Modulate neuroinflammation
Improve behavioral and psychological symptoms

Depression comorbidity: High depression prevalence in AD patients linked to serotonergic changes:

Bidirectional relationship between depression and AD risk
5-HTTLPR may modify AD risk in depressed patients

Parkinson's Disease

In Parkinson's disease, serotonergic dysfunction significantly impacts non-motor symptoms [@vermeulen2020]:

Depression in PD:

SLC6A4 variants associated with depression in PD patients
5-HTTLPR may predict antidepressant response
Serotonergic degeneration precedes dopaminergic loss in some cases

SSRI use in PD:

SSRIs commonly used for depression in PD
May affect levodopa efficacy through pharmacodynamic interactions
Potential for serotonin syndrome with MAO-B inhibitors

Non-motor symptoms:

Serotonergic dysfunction contributes to depression, anxiety, sleep disorders
Olfactory dysfunction linked to serotonergic changes
Fatigue may relate to transporter function

Locus coeruleus and raphe:

Both noradrenergic and serotonergic systems affected in PD
May explain comorbid depression and anxiety
Lewy bodies found in serotonergic neurons

Other Neurodegenerative Conditions

Migraine: Altered platelet SERT in some patients
Epilepsy: Some evidence for SERT involvement
Multiple sclerosis: Serotonergic changes reported
Amyotrophic lateral sclerosis: Reduced serotonergic markers
Huntington's disease: Serotonergic dysfunction prominent

Clinical Significance

SSRIs and Pharmacotherapy

SLC6A4 is the primary target of selective serotonin reuptake inhibitors (SSRIs), which block serotonin reuptake, increasing synaptic 5-HT levels:

Mechanism of Action

Acute effect: Blocking reuptake increases extracellular 5-HT

Downstream changes: Receptor desensitization over weeks

Neuroplasticity: Enhanced neurogenesis and synaptic plasticity

Delayed onset: Benefits typically take 2-4 weeks

Therapeutic Implications

SSRI response: SLC6A4 genotype may predict treatment response

L allele may show better response in some studies
S allele associated with poorer response and treatment resistance

2. Side effects:

GI symptoms (initial)
Sexual dysfunction (long-term)
Insomnia
Weight changes

3. Discontinuation: Tapering required to avoid discontinuation syndrome

Treatment resistance: ~30-50% of patients do not respond adequately

Other Target Drugs

Serotonin-norepinephrine reuptake inhibitors (SNRIs): Venlafaxine, duloxetine
Tricyclic antidepressants (TCAs): Some (e.g., clomipramine)
Monoamine oxidase inhibitors (MAOIs): Indirect effects

Expression Patterns

Brain Expression

SLC6A4 is expressed in:

Raphe nuclei: Primary site of serotonin neuron cell bodies in midbrain and brainstem
Hippocampus: Modulates memory, emotion, and neuroplasticity
Cortex: Involved in higher cognitive functions
Basal ganglia: Motor and reward regulation
Amygdala: Emotional processing and fear conditioning
Thalamus: Sensory and regulatory functions
Hypothalamus: Neuroendocrine regulation

Cell Type Expression

Presynaptic serotonin neurons: Highest expression
Astrocytes: Low expression
Platelets: High SERT expression — used as peripheral model
Enterochromaffin cells: Gut serotonin storage and release
Lung: Minor expression

Species Differences

Mouse SERT shows 92% homology to human
Different 5-HTTLPR structure in rodents
Expression patterns conserved across mammals

Molecular Pathways and Interactions

Signaling Interactions

GPCR interactions: Serotonin receptors modulate SERT function

Scaffold proteins: PSD-95, SNX27 regulate trafficking

Kinases: PKC, PKA, MAPK affect activity

Phosphatases: Calcineurin can dephosphorylate SERT

Research Directions

Current Understanding

SLC6A4 is essential for serotonin homeostasis
Genetic variants influence disease risk and treatment response
SSRIs remain first-line depression treatment
Role in neurodegeneration actively investigated
PET ligands allow in vivo imaging of SERT

Knowledge Gaps

Mechanisms of SSRI resistance
Role in specific neurodegenerative processes
Biomarker potential
Real-world pharmacogenomics implementation
Novel treatment approaches (rapid-acting antidepressants)

Key Publications

[Murphy DL, et al. (2008) Serotonin transporter: gene, gene boundaries, and haplotypes. Cell Mol Neurobiol 28:299-330](https://pubmed.ncbi.nlm.nih.gov/18215985/)

[Lesch KP, et al. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531](https://pubmed.ncbi.nlm.nih.gov/8758948/)

[Canli T, Lesch KP. (2006) Serotonin transporter gene and stress: a tale of two promoters. Neuropsychopharmacology 31:288-294](https://pubmed.ncbi.nlm.nih.gov/16319898/)

[Stocker CJ, et al. (2006) Serotonin transporter gene polymorphism and Alzheimer's disease. J Neurol Neurosurg Psychiatry 77:688-690](https://pubmed.ncbi.nlm.nih.gov/16484651/)

[Vermeulen E, et al. (2020) Serotonergic dysfunction in Parkinson's disease: a systematic review. J Parkinsons Dis 10:1645-1658](https://pubmed.ncbi.nlm.nih.gov/33280117/)

[Hauser RA, et al. (2021) Serotonin and Parkinson's disease: a systematic review. Parkinsonism Relat Disord 82:29-35](https://pubmed.ncbi.nlm.nih.gov/33419653/)

[Blier P, El Mansari M. (2008) Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 363:2563-2575](https://pubmed.ncbi.nlm.nih.gov/18801849/)

[Kahn RS, et al. (2008) Serotonin transporter polymorphisms and sustained response to antidepressants. J Clin Psychopharmacol 28:497-501](https://pubmed.ncbi.nlm.nih.gov/18520979/)

[Rudolph LM, et al. (2023) Serotonin in neurodevelopment and neuropsychiatric disease. Neuroscience 519:1-24](https://pubmed.ncbi.nlm.nih.gov/37276028/)

[Ressler KJ, Nemeroff CB. (2012) Role of serotonergic system in the pathophysiology of depression and anxiety disorders. Depress Anxiety 29:460-468](https://pubmed.ncbi.nlm.nih.gov/21538641/)

External Links

[NCBI Gene: SLC6A4](https://www.ncbi.nlm.nih.gov/gene/6532)
[UniProt: P31645](https://www.uniprot.org/uniprot/P31645)
[Ensembl: ENSG00000108576](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108576)
[Human Protein Atlas](https://www.proteinatlas.org/ENSG00000108576-SLC6A4)

Pathway Diagram

The following diagram shows the key molecular relationships involving SLC6A4 Gene — Serotonin Transporter discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

SLC6A4

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-slc6a4
kg_node_id	SLC6A4
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-99b838b8887a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-slc6a4'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

36

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

SLC6A4 Gene — Serotonin Transporter

SLC6A4 Gene — Solute Carrier Family 6 Member 4

SLC6A4 Gene — Solute Carrier Family 6 Member 4

Pathway Diagram

SLC6A4 Gene — Solute Carrier Family 6 Member 4

Introduction

Gene Information

Genomic Structure

Regulatory Polymorphisms

5-HTTLPR (Serotonin-Transporter-Linked Polymorphic Region)

STin2 VNTR

Protein Structure and Function

Structural Features

Transport Mechanism

Substrate Specificity

Conformational Cycle

Regulation of SLC6A4

Transcriptional Regulation

Post-Translational Regulation

Membrane Trafficking

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Conditions

Clinical Significance

SSRIs and Pharmacotherapy

Mechanism of Action

Therapeutic Implications

Other Target Drugs

Expression Patterns

Brain Expression

Cell Type Expression

Species Differences

Molecular Pathways and Interactions

Signaling Interactions

Related Proteins

Research Directions

Current Understanding

Knowledge Gaps

Key Publications

See Also

External Links

Pathway Diagram

💬 Discussion